ALLO-2
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558425

CAS#: 1357350-60-7

Description: ALLO-2 is a Inhibitor of Drug-Resistant Smo Mutant.

Chemical Structure

img
ALLO-2
CAS# 1357350-60-7
Instruction

Theoretical Analysis

MedKoo Cat#: 558425
Name: ALLO-2
CAS#: 1357350-60-7
Chemical Formula: C18H12F3N5O
Exact Mass: 371.10
Molecular Weight: 371.320
Elemental Analysis: C, 58.22; H, 3.26; F, 15.35; N, 18.86; O, 4.31

Price and Availability

Size Price Availability Quantity
10mg USD 785 2 Weeks
25mg USD 1550 2 Weeks
Bulk inquiry

Synonym: ALLO-2; ALLO 2; ALLO2;

IUPAC/Chemical Name: N-[4-[4-(Trifluoromethoxy)phenyl]-2-pyrimidinyl]-1H-indazol-5-amine

InChi Key: QTYGEBIJNWMVCW-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H12F3N5O/c19-18(20,21)27-14-4-1-11(2-5-14)15-7-8-22-17(25-15)24-13-3-6-16-12(9-13)10-23-26-16/h1-10H,(H,23,26)(H,22,24,25)

SMILES Code: FC(F)(F)OC1=CC=C(C2=NC(NC3=CC4=C(NN=C4)C=C3)=NC=C2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 371.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, Hancock L, Morris E, Cairo MS. New frontiers in pediatric Allo-SCT. Bone Marrow Transplant. 2014 Sep;49(9):1139-45. doi: 10.1038/bmt.2014.89. Epub 2014 May 12. Review. PubMed PMID: 24820213; PubMed Central PMCID: PMC4439009.

2: Trailin AV, Pleten MV, Nikonenko AS, Efimenko NE, Ostapenko TI. [URINE UNDER CHRONIC DYSFUNCTION OF RENAL ALLO-TRANSPLANT]. Klin Lab Diagn. 2015 Nov;60(11):31-7. Russian. PubMed PMID: 26999863.

3: Wang L, Liu H, Zheng C, Tang B, Zhu X, Yao W, Zhang L, Sun Z. [Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia]. Zhonghua Yi Xue Za Zhi. 2014 Nov 4;94(40):3150-3. Chinese. PubMed PMID: 25573310.

4: Holm AM, Riise GC, Hansson L, Brinch L, Bjørtuft O, Iversen M, Simonsen S, Fløisand Y. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant. 2013 May;48(5):703-7. doi: 10.1038/bmt.2012.197. Epub 2012 Oct 15. PubMed PMID: 23064037.

5: Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, Granata A, Bouabdallah R, Coso D, Chabannon C, Balzarotti M, Santoro A, Blaise D. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 2013 Feb;48(2):249-52. doi: 10.1038/bmt.2012.116. Epub 2012 Jun 25. PubMed PMID: 22732704.

6: Moncharmont P, Rigal D. [Association of red blood cell and platelet allo-antibodies in platelet alloimmunized patients]. Transfus Clin Biol. 2014 Jun;21(3):99-102. doi: 10.1016/j.tracli.2014.05.004. Epub 2014 Jun 16. French. PubMed PMID: 24948207.

7: Tsuma Y, Imamura T, Ichise E, Sakamoto K, Ouchi K, Osone S, Ishida H, Wada T, Hosoi H. Successful treatment of idiopathic colitis related to XIAP deficiency with allo-HSCT using reduced-intensity conditioning. Pediatr Transplant. 2015 Feb;19(1):E25-8. doi: 10.1111/petr.12405. Epub 2014 Nov 21. PubMed PMID: 25412586.

8: Zhu F, Chen HR, Guo Z, Liu XD, He XP, Lou JX, Yang K, Zhang Y, Chen P. [Therapeutic efficacy of second allo-HSCT for aplastic anemia after failure of first allo-HSCT]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1348-53. doi: 10.7534/j.issn.1009-2137.2014.05.032. Chinese. PubMed PMID: 25338587.

9: Aizawa S, Sado T. Manifestation of allo H-2-restriction specificity by self H-2-restricted T cells. Cell Immunol. 1990 Oct 1;130(1):1-10. PubMed PMID: 2397498.

10: Xu H, Perez SD, Cheeseman J, Mehta AK, Kirk AD. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant. 2014 Feb;14(2):319-32. doi: 10.1111/ajt.12574. PubMed PMID: 24472192; PubMed Central PMCID: PMC3906634.

11: Braamse AM, van Meijel B, Visser O, Huijgens PC, Beekman AT, Dekker J. Distress, problems and supportive care needs of patients treated with auto- or allo-SCT. Bone Marrow Transplant. 2014 Feb;49(2):292-8. doi: 10.1038/bmt.2013.155. Epub 2013 Oct 7. PubMed PMID: 24096825.

12: Hu J, Wang L, Li Y, Qiu Z, Xu W, Sun Y, Yin Y, Liu W, Ou J, Wang M, Wang W, Liang Z, Cen X, Ren H. [Efficacy comparison between Ph⁺ ALL patients treated with chemotherapyplus tyrosine kinase inhibitors followed by allo-HSCT and Ph-ALL patients with allo-HSCT: a case control study from a single center]. Zhonghua Xue Ye Xue Za Zhi. 2015 Jul;36(7):593-7. doi: 10.3760/cma.j.issn.0253-2727.2015.07.014. Chinese. PubMed PMID: 26304085.

13: Pham BN, Roussel M, Peyrard T, Beolet M, Jan-Lasserre V, Gien D, Ripaux M, Bourgouin S, Kappler-Gratias S, Rouger P, Le Pennec PY. Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies? Transfusion. 2011 Dec;51(12):2679-85. doi: 10.1111/j.1537-2995.2011.03207.x. Epub 2011 Jun 9. PubMed PMID: 21658048.

14: Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients. Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11. PubMed PMID: 22684047.

15: Tiwari AK, Dara RC, Arora D, Aggarwal G, Rawat G, Mitra S, Prashant PK, Raina V. Allo-antibody identification: a software approach! Transfus Apher Sci. 2014 Oct;51(2):197-202. doi: 10.1016/j.transci.2014.08.020. Epub 2014 Aug 27. PubMed PMID: 25217458.

16: Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27. PubMed PMID: 27118410.

17: Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, Fenske TS. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014 Jan;49(1):1-7. doi: 10.1038/bmt.2013.72. Epub 2013 May 27. Review. PubMed PMID: 23708703.

18: Takekiyo T, Dozono K, Mitsuishi T, Murayama Y, Maeda A, Nakano N, Kubota A, Tokunaga M, Takeuchi S, Takatsuka Y, Utsunomiya A. Effect of exercise therapy on muscle mass and physical functioning in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2015 Apr;23(4):985-92. doi: 10.1007/s00520-014-2425-7. Epub 2014 Sep 27. PubMed PMID: 25256376.

19: Dong L, Yuan C, Orlando BJ, Malkowski MG, Smith WL. Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. J Biol Chem. 2016 Dec 2;291(49):25641-25655. Epub 2016 Oct 18. PubMed PMID: 27756840; PubMed Central PMCID: PMC5207261.

20: Wei J, Xu J, Cao Y, Zhou J, Zhang Y. Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis. Acta Haematol. 2015;133(2):136-44. doi: 10.1159/000358579. Epub 2014 Sep 20. Review. PubMed PMID: 25247746.